Objective: Determine whether reconstitution of Vg2Vd2 T cells in patients with HIV is due to new cell synthesis with recovery of the T-cell receptor repertoire or proliferative expansion of residual cells from the time of treatment initiation.
Introduction

HIV infection causes specific depletion of CD4-negative Vg2Vd2 T cells (a subset of gd T cells) in patients with
HIV disease [1, 2] . Vg2Vd2 T-cell depletion is remarkably consistent among individuals with HIV disease and may occur when Envelope glycoprotein binds to elevated levels of CCR5, which activates caspase and causes cell death; CCR5 levels are very high in these cells [3] . Prolonged antiretroviral therapy (ART) appears to reconstitute Vg2Vd2 T cells [4] . Untreated natural virus suppressors (viral loads <400 RNA copies/ml of blood in the absence of ART [5] ) also called elite controllers, had Vg2Vd2 T-cell counts similar to uninfected controls, but the Vg2 repertoire was damaged [6] , and higher cell counts reflected expansion of the residual population [7] . Untreated HIV-positive patients with persistent low-level viremia had low Vg2Vd2 T cells [8] and significant damage to the T-cell receptor (TCR) repertoire [2] .
Here, we compared the Vg2 repertoires (also designated Vg9 in an alternate nomenclature) among three groups of HIV patients to determine the mechanism for Vg2Vd2 T-cell reconstitution after long-term virus suppression. We focus on public Vg2 chains found in many unrelated individuals due to the lack of major histocompatibility complex (MHC) restriction for gd T-cell antigen responses [9] ; at least eight public clonotypes were found in more than 50% of all healthy volunteers [10] .
Comparing the presence or absence of these public Vg2 chains among HIV-positive groups defines the extent of depletion or reconstitution of the TCR repertoire.
Results
Peripheral blood mononuclear cells from four groups: patients receiving ARTand having CD4 counts above 300 cells/ml (ART), natural virus suppressors who control HIV to undetectable levels in the absence of therapy (NVS), patients with chronic viremia not receiving therapy (VIR), and HIV-negative controls. Specimens were used for cloning cDNA for individual Vg2 chains, followed by analysis of the T-cell receptor repertoire (Supplemental digital content Table 1 and Methods, http://links.lww. com/QAD/A342). Approximately 250 Vg2 chain sequences were analyzed for each patient or control specimen. In control donors, more than 60% have the Vg2-Jg1.2 rearrangement. All HIV-infected patients had profound depletion of phosphoantigen-reactive Vg2-Jg1.2 chains (Fig. 1b ). This value was as low as 10% for the VIR group. For the ARTand NVS groups, Vg2-Jg1.2 comprised approximately 30% of all Vg2 chains.
The normal Vg2 repertoire is dominated by public clonotypes [11] , each of which is encoded by multiple nucleotypes. We matched Vg2 clonotype sequences from our HIV-positive groups to a table of public clonotypes from HIV-negative African Americans (Supplemental Digital Content Table 2 , http://links.lww.com/QAD/ A342) [10] . A significant decrease among public clonotypes was apparent for the ART, NVS, and VIR groups. In healthy controls, 52% of all Vg2-Jg1.2 rearrangements were public clonotypes (Fig. 1c ). The NVS group had approximately 20%, a result similar to the VIR group. The ART group had approximately 30% public Vg2 clonotypes, a value lower than controls but higher than other HIV-infected groups. Our earlier studies implied higher levels of Vg2-Jg1.2 cells in ART compared to other groups, but did not enumerate public clonotypes [4, 12] .
Next, we examined the distribution of nucleotypes for several of the most common public clonotypes including (PubSeq1) (Fig. 1c ). PubSeq1 was encoded by five different nucleotypes in controls and ART patients, but was less frequent in NVS or VIR groups (Supplemental digital content Table 3 , http://links.lww.com/QAD/ A342). Controls had an average of 2.4 nucleotypes for PubSeq1; values were lower in all HIV-positive groups. However, we found examples where nucleotype abundance was similar to controls even though clonotype expression was lower (e.g. PubSeq2 for ART and NVS groups). For PubSeq6 and PubSeq7 there were substantial defects in both clonotype and nucleotype expression for all HIV-positive groups. PubSeq8 had low clonotype abundance for all HIV-positive groups, but nucleotype levels were similar to controls for ART and NVS groups.
For the VIR group, five of the seven patients had PubSeq1 and only one patient had more than one nucleotype ( Fig. 1c ). For PubSeq2, two of the seven VIR and six of the eight controls had this clonotype. Patients in the NVS group were likely to express PubSeq1 (five of nine) or PubSeq2 (four of nine). Most surprising was the group of ART patients where all the eight patients expressed PubSeq1 with an average of 1.9 nucleotypes per person ( Fig. 1c ). Thus, every control or ART patient had PubSeq1 and had similar nucleotype abundance. When PubSeq1 was present in NVS or VIR groups, it was encoded by nine nucleotypes in five of the NVS patients (average 1.8) and seven nucleotypes in five of the VIR Vg2 patients (average 1.4). Patient 5 in the ART group showed strong selection for PubSeq1 (three nucleotypes), PubSeq2 (three nucleotypes), and the less frequent PubSeq8. A similar pattern was seen for patient #2 of the NVS group who had three nucleotypes encoding PubSeq1 and six nucleotypes encoding PubSeq2. Surprisingly, nucleotype diversity for ART or NVS patients was sometimes greater than for uninfected controls and we found several nucleotypes that were not present in control groups. Whether these Vg2 sequences are selected for their response to HIV, another infectious agent, malignancy, or unknown pathology could not be determined.
T-cell receptor-Vg2 repertoires are similar for antiretroviral therapy and uninfected control groups Individual TCR repertoires are complex because of clonal diversity (increasing the number of unique TCR sequences) and selection, which causes individual clones to be present above or below the population averages. In 'shallow' sequencing studies like ours, the Vg2 sequence sample size (about 250 sequences per sample) is below the number required to cover an entire repertoire. Most Vg2 sequences are present once within each sample set and a few are present at higher, and sometimes much higher frequencies. Specialized statistical methods are required to make group-wise comparisons of repertoire complexity (see online Methods). One approach is to compare, between groups, the level of similarity between pairs of individual repertoires within each group [13, 14] .
We compared the appearance of common clonotypes between pairs of individual repertoires. Differences in the median number of common clonotypes per group between control and ART patients were not statistically significant ( Fig. 2a ). There were significantly more common clonotypes between the control and ART groups compared with NVS, or between the control and VIR groups. We calculated the Morisita-Horn similarity index between pairs of clonotype repertoires in each group, which measures the abundance of individual clonotypes (or nucleotypes) and total number of clonotypes (or nucleotypes) in pair-wise comparisons; significant differences were observed between control and all other groups and there was a trend to lower similarity indices for NVS and VIR groups (Fig. 2b) . Statistically significant differences in Morisita-Horn similarity indices between control and ART groups reflect differences in the abundance of common clonotypes, showing the ART group is actually more heterogeneous than the control group. Similar results were obtained when comparing the numbers of common nucleotypes (Fig. 2c) . The Morisita-Horn similarity analysis for nucleotype repertoires showed significantly greater similarity in the control group compared with either NVS or VIR repertoires and in ART compared with NVS groups (Fig. 2d ). Again, control and ART groups were distinguishable from the NVS and VIR groups in terms of nucleotype complexity.
Discussion
Profound depletion of CD4-negative Vg2Vd2 T cells in HIV disease is specific for cells expressing a Vg2-Jg1.2Vd2 TCR [1] , the same receptor that recognizes stimulatory phosphoantigens [15] [16] [17] and tumor cells [18] [19] [20] . Now, nearly 10 years after the introduction of combination therapy, we can assess the long-term effects of virus suppression on reconstitution of the Vg2Vd2 TCR repertoire.
Focusing on gd T cells is a new approach for studying treatment effects. Immune reconstitution in HIV disease is usually judged by treatment-associated increases in the CD4 þ T-cell count [21] which are related to fewer opportunistic infections and improved responses to vaccination [22] . The extent of CD4 þ T-cell reconstitution has been related to nadir CD4 cell count [23] and the duration of viremia prior to treatment [24] .
Proliferative expansion of surviving CD4 þ T cells is one model for immune reconstitution [25] . This mechanism would increase CD4 cell counts without affecting TCR complexity. Alternately, reconstitution of CD4 þ T cells by de-novo thymic output would increase both counts and repertoire complexity. Studies on TCR recombination excisional circles (TRECs), a byproduct of TCR rearrangement [26] , and phenotypically defined recent thymic emigrants [27] supported thymic output as the driver of immune reconstitution. Using spectratyping methods, the TCR Vb repertoire complexity was increasing during reconstitution [28] although spectratype data are not corrected for sample size effects which can be especially important for low CD4 þ cell counts, and expansion of individual clones can skew the spectratype and confuse interpretation of data. Sequencing studies are needed to confirm whether reconstitution is associated with increasing TCR repertoire complexity due to new cell synthesis. However, the large size of the TCR Vb repertoire with more than 10 5 rearranged sequences in healthy adults, and MHC restriction differences reduce the frequency of public clonotypes. These technical issues are obstacles to proving whether or not reconstitution is associated with increased TCR repertoire complexity.
Knowing that the thymus produces gd, CD4ab and CD8ab T cells from the same precursor cell pool [29] , reconstitution of the CD4 þ TCR repertoire must be matched by similar changes in the gd TCR repertoire. Our finding that ART reconstitutes Vg2 repertoire complexity supports the thymic output model for immune reconstitution of both gd and CD4 þ T cells. Although these are cross-sectional studies, our earlier work documented near-extinction of Vg2-Jg1.2 sequences in viremic patients with CD4 þ T-cell counts below 200 cells/ml [2] . All patients in the ART group had nadir CD4 þ cell counts below 200 cells/ml two of them with nadir CD4 þ below 70 cells/ml. In our experience, it is unlikely that these individuals with such low nadir CD4 þ cell counts were harboring substantial Vg2-Jg1.2 cells in blood. Surviving gd T cells sequestered in tissues are unlikely to account for repertoire changes because longitudinal studies on patients initiating combination ART did not detect a rapid rebound in Vg2Vd2 T cells [2] . The increased complexity of reconstituted gd TCR repertoire should be matched by similar changes in the ab TCR repertoire in CD4 þ cells, a result consistent with some recent studies [30] .
Even though treatment reconstituted the Vg2 chain receptor repertoire, functional responses to phosphoantigen were not restored fully [12] . We did find that bisphosphonate (zoledronate) induced Vg2Vd2 cell proliferation and antibody-dependent cellular cytotoxicity (ADCC) in HIV-positive patients who had received ART [31] . Bisphosphonate treatment has been developed as an immunotherapy for cancer, by increasing tumor cytolysis or elevating ADCC activity [32, 33] , and was well tolerated by HIV patients [34] . Knowing that treated HIV patients can recover a functional Vg2 chain repertoire and their effector function can be stimulated by bisphosphonates, we are encouraged to initiate bisphosphonate therapy studies in patients with HIV disease.
